Federica Vanoni1,2, Francesca Minoia3, Clara Malattia4. 1. Department of Pediatrics, Ospedale San Giovanni, 6500, Bellinzona, Switzerland. Federica.Vanoni@eoc.ch. 2. Unité Romande d'Immuno-rhumatologie Pédiatrique (URIRP), Département Femme-Mère-Enfant (DFME), CHUV, University of Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland. Federica.Vanoni@eoc.ch. 3. Istituto Giannina Gaslini, Genoa, Italy. 4. Istituto Giannina Gaslini and Università degli Studi di Genova, Genoa, Italy.
Abstract
In the past years, pediatric rheumatology has seen a revolution in the treatments for rheumatic diseases, particularly juvenile idiopathic arthritis. Even if nonsteroidal anti-inflammatory drugs (NSAID), intra-articular corticosteroids (IAC) injections, and methotrexate remain the mainstay of the treatment for JIA patients, in aggressive disease, these treatments may be not sufficient to reach disease remission and to prevent long-term disability. Comprehension of immunological mechanisms involved in the pathogenesis of the diseases allowed to conceive new drugs targeting specific steps of the immune response. Several cytokines, like TNF alpha and IL-1, represent a very interesting target for biologic therapies. Due to the efficacy of these therapies, nowadays, "disease remission" in pediatric rheumatology is more and more frequent, especially in juvenile idiopathic arthritis patients, and the long-term outcomes have been significantly improved. Crucial to these advancements have been multicenter controlled clinical trials and long-term safety monitoring. CONCLUSIONS: Research in pediatric rheumatology has resulted in dramatic advances in diseases management. Biologic treatments have improved physical and functional outcomes and quality of life of patients with rheumatic disease. What is Known: • NSAID, intra-articular injection of corticoids, and methotrexate are the mainstay in treatment of JIA. • In aggressive JIA, these treatments may be not sufficient to reach disease remission and to prevent long term disability. What is New: • In recent years, management of JIA has significantly improved with the development of biologic therapies that allowed children with arthritis to reach a normal growth and to achieve a good long-term functional outcome.
In the past years, pediatric rheumatology has seen a revolution in the treatments for rheumatic diseases, particularly juvenile idiopathic arthritis. Even if nonsteroidal anti-inflammatory drugs (NSAID), intra-articular corticosteroids (IAC) injections, and methotrexate remain the mainstay of the treatment for JIA patients, in aggressive disease, these treatments may be not sufficient to reach disease remission and to prevent long-term disability. Comprehension of immunological mechanisms involved in the pathogenesis of the diseases allowed to conceive new drugs targeting specific steps of the immune response. Several cytokines, like TNF alpha and IL-1, represent a very interesting target for biologic therapies. Due to the efficacy of these therapies, nowadays, "disease remission" in pediatric rheumatology is more and more frequent, especially in juvenile idiopathic arthritispatients, and the long-term outcomes have been significantly improved. Crucial to these advancements have been multicenter controlled clinical trials and long-term safety monitoring. CONCLUSIONS: Research in pediatric rheumatology has resulted in dramatic advances in diseases management. Biologic treatments have improved physical and functional outcomes and quality of life of patients with rheumatic disease. What is Known: • NSAID, intra-articular injection of corticoids, and methotrexate are the mainstay in treatment of JIA. • In aggressive JIA, these treatments may be not sufficient to reach disease remission and to prevent long term disability. What is New: • In recent years, management of JIA has significantly improved with the development of biologic therapies that allowed children with arthritis to reach a normal growth and to achieve a good long-term functional outcome.
Authors: Sarah Ringold; Pamela F Weiss; Robert A Colbert; Esi Morgan DeWitt; Tzielan Lee; Karen Onel; Sampath Prahalad; Rayfel Schneider; Susan Shenoi; Richard K Vehe; Yukiko Kimura Journal: Arthritis Care Res (Hoboken) Date: 2014-07 Impact factor: 4.794
Authors: Ekaterina I Alexeeva; Saniya I Valieva; Tatyana M Bzarova; Elena L Semikina; Kseniya B Isaeva; Alexander O Lisitsyn; Rina V Denisova; Evgeniya G Chistyakova Journal: Clin Rheumatol Date: 2011-03-08 Impact factor: 2.980
Authors: Sarah Ringold; Pamela F Weiss; Timothy Beukelman; Esi Morgan DeWitt; Norman T Ilowite; Yukiko Kimura; Ronald M Laxer; Daniel J Lovell; Peter A Nigrovic; Angela Byun Robinson; Richard K Vehe Journal: Arthritis Rheum Date: 2013-10
Authors: F Atzeni; R Talotta; F Salaffi; A Cassinotti; V Varisco; M Battellino; S Ardizzone; F Pace; P Sarzi-Puttini Journal: Autoimmun Rev Date: 2012-11-30 Impact factor: 9.754
Authors: Nicolino Ruperto; Daniel J Lovell; Pierre Quartier; Eliana Paz; Nadina Rubio-Pérez; Clovis A Silva; Carlos Abud-Mendoza; Ruben Burgos-Vargas; Valeria Gerloni; Jose A Melo-Gomes; Claudia Saad-Magalhães; Flavio Sztajnbok; Claudia Goldenstein-Schainberg; Morton Scheinberg; Immaculada Calvo Penades; Michael Fischbach; Javier Orozco; Philip J Hashkes; Christine Hom; Lawrence Jung; Loredana Lepore; Sheila Oliveira; Carol A Wallace; Leonard H Sigal; Alan J Block; Allison Covucci; Alberto Martini; Edward H Giannini Journal: Lancet Date: 2008-07-14 Impact factor: 79.321
Authors: Daniel J Lovell; Nicolino Ruperto; Steven Goodman; Andreas Reiff; Lawrence Jung; Katerina Jarosova; Dana Nemcova; Richard Mouy; Christy Sandborg; John Bohnsack; Dirk Elewaut; Ivan Foeldvari; Valeria Gerloni; Jozef Rovensky; Kirsten Minden; Richard K Vehe; L Wagner Weiner; Gerd Horneff; Hans-Iko Huppertz; Nancy Y Olson; John R Medich; Roberto Carcereri-De-Prati; Melissa J McIlraith; Edward H Giannini; Alberto Martini Journal: N Engl J Med Date: 2008-08-21 Impact factor: 91.245
Authors: Ian D Ferguson; Patricia Griffin; Joshua J Michel; Hiroshi Yano; Sarah L Gaffen; Robert G Mueller; Jeffrey A Dvergsten; Jon D Piganelli; Margalit E Rosenkranz; Daniel A Kietz; Abbe N Vallejo Journal: Front Immunol Date: 2018-08-06 Impact factor: 7.561
Authors: Linde N Nijhof; Merel M Nap-van der Vlist; Elise M van de Putte; Annet van Royen-Kerkhof; Sanne L Nijhof Journal: Rheumatol Int Date: 2018-08-23 Impact factor: 2.631
Authors: Laura Maggi; Alessio Mazzoni; Rolando Cimaz; Francesco Liotta; Francesco Annunziato; Lorenzo Cosmi Journal: Front Immunol Date: 2019-03-14 Impact factor: 7.561
Authors: Franz Thiele; Ariane Klein; Daniel Windschall; Anton Hospach; Ivan Foeldvari; Kirsten Minden; Frank Weller-Heinemann; Gerd Horneff Journal: Rheumatol Int Date: 2021-02-16 Impact factor: 2.631